Skip to main content

Advertisement

SpringerLink
Log in

An overview of the efficacy of phototherapy in oncodermatology

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Cutaneous adverse events (AEs) following cancer immunotherapy, targeted therapy, and chemotherapy have been well-documented in the literature. A number of case reports have identified phototherapy, a form of light therapy that mimics sunlight exposure, as a noninvasive treatment modality for these cutaneous toxicities. By inducing local suppression of the immune system, phototherapy is a skin-directed treatment with minimal effect on tumor response. Phototherapy may therefore be a viable treatment option for cutaneous AEs from cancer therapies.

Methods

We reviewed the literature for patients treated with phototherapy for cutaneous AEs following cancer immunotherapy, targeted therapy, or chemotherapy. We also included three previously unpublished cases from our own institution.

Results

We identified 24 patients (80% male, mean age 67 years, range 49–75 years). Patients received the following phototherapy types: NB-UVB (n = 17), PUVA (n = 6), or PDT (n = 1). A topical steroid was used in conjunction with phototherapy in seven patients. At phototherapy onset, cancer treatment was either continued, temporarily discontinued, or discontinued (n = 9, 6, 7, respectively; in two cases, the cancer treatment course was unknown). Improvement of cutaneous AEs was observed in 96% of patients.

Conclusions

Phototherapy resulted in full or partial improvement in all but one patient. A topical steroid was used in nearly a third of patients, suggesting some oncodermatologists co-administer topicals to further boost response. Continuation of cancer therapy in the majority of patients highlights an additional advantage of phototherapy. We believe phototherapy may be an effective adjunctive treatment to topical steroids when treating these cutaneous toxicities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Availability of data and material

Not applicable.

Code availability

Not applicable.

References

  1. Plachouri KM, Vryzaki E, Georgiou S (2019) Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. Curr Drug Saf 14(1):14–20. https://doi.org/10.2174/1574886313666180730114309

    Article  CAS  PubMed  Google Scholar 

  2. Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19(3):345–361. https://doi.org/10.1007/s40257-017-0336-3

    Article  PubMed  Google Scholar 

  3. Lin WH, Lee KY, Lee WR, Shih YH (2020) Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment. J Dermatol 47(9):1041–1045. https://doi.org/10.1111/1346-8138.15371

    Article  CAS  PubMed  Google Scholar 

  4. Donaldson M, Owen JL, Chae YK, Choi JN (2018) Management of persistent pruritus and lichenoid reaction secondary to nivolumab with narrowband ultraviolet b phototherapy. Front Oncol 8:405. https://doi.org/10.3389/fonc.2018.00405

    Article  PubMed  PubMed Central  Google Scholar 

  5. Walker D, Jacobe H (2011) Phototherapy in the age of biologics. Semin Cutan Med Surg 30(4):190–198. https://doi.org/10.1016/j.sder.2011.08.004

    Article  CAS  PubMed  Google Scholar 

  6. Meriggi F, Zaniboni A (2021) Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature. Cancer Immunol Immunother 70(6):1511–1517. https://doi.org/10.1007/s00262-020-02786-3

    Article  CAS  PubMed  Google Scholar 

  7. Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR (2018) Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 6(1):51. https://doi.org/10.1186/s40425-018-0371-5

    Article  PubMed  PubMed Central  Google Scholar 

  8. Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS (2019) Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 80(4):990–997. https://doi.org/10.1016/j.jaad.2018.10.062

    Article  CAS  PubMed  Google Scholar 

  9. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 72(2):203–218. https://doi.org/10.1016/j.jaad.2014.07.032

    Article  CAS  PubMed  Google Scholar 

  10. Evan A, Green R, Schuchter L (2002) Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14(2):212–216. https://doi.org/10.1097/00001622-200203000-00012

    Article  Google Scholar 

  11. Brahmer JR, Abu-Sbeih H, Ascierto PA (2021) Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435. https://doi.org/10.1136/jitc-2021-002435

    Article  PubMed  PubMed Central  Google Scholar 

  12. Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(4):i119–i142. https://doi.org/10.1093/annonc/mdx225

    Article  Google Scholar 

  13. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Chakrabarty JH, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, in collaboration with the National Comprehensive Cancer Network, (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO.2017.77.6385

    Article  CAS  PubMed  Google Scholar 

  14. Mehta D, Lim HW (2016) Ultraviolet B phototherapy for psoriasis: review of practical guidelines. Am J Clin Dermatol 17(2):125–133. https://doi.org/10.1007/s40257-016-0176-6

    Article  PubMed  Google Scholar 

  15. Hung CT, Chiang CP, Wu BY (2012) Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy. J Dermatol 39(12):1076–1077. https://doi.org/10.1111/j.1346-8138.2012.01615.x

    Article  PubMed  Google Scholar 

  16. Zubair R, Hamzavi IH (2020) Phototherapy for vitiligo. Dermatol Clin 38(1):55–62. https://doi.org/10.1016/j.det.2019.08.005

    Article  CAS  PubMed  Google Scholar 

  17. Morita A (2018) Current developments in phototherapy for psoriasis. J Dermatol 45(3):287–292. https://doi.org/10.1111/1346-8138.14213

    Article  CAS  PubMed  Google Scholar 

  18. Huu DL, Minh TN, Van TN, Minh PPT, Huu ND, Cam VT, Huyen ML, Nguyet MV, Thi ML, Thu HDT, Hau KT, Gandolfi M, Satolli F, Feliciani C, Tirant M, Vojvodic A, Lotti T (2019) The effectiveness of narrow band Uvb (Nb-Uvb) in the treatment of pityriasis lichenoides chronica (PLC) in Vietnam. Open Access Maced J Med Sci 7(2):221–223. https://doi.org/10.3889/oamjms.2019.055

    Article  PubMed  PubMed Central  Google Scholar 

  19. Maranda EL, Smith M, Nguyen AH, Patel VN, Schachner LA, Joaquin JJ (2016) Phototherapy for pityriasis lichenoides in the pediatric population: a review of the published literature. Am J Clin Dermatol 17(6):583–591. https://doi.org/10.1007/s40257-016-0216-2

    Article  PubMed  Google Scholar 

  20. Shenoi SD, Prabhu S, Association I, of Dermatologists, Venereologists and Leprologists, (2014) Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol 80(6):497–504. https://doi.org/10.4103/0378-6323.144143

    Article  PubMed  Google Scholar 

  21. Rkein AM, Ozog DM (2014) Photodynamic therapy. Dermatol Clin 32(3):415–425. https://doi.org/10.1016/j.det.2014.03.009

    Article  CAS  PubMed  Google Scholar 

  22. Bulat V, Situm M, Dediol I, Ljubicić I, Bradić L (2011) The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol 35(2):147–151

    PubMed  Google Scholar 

  23. Zhang L, Wang X, Chen S, Zhao J, Wu J, Jiang M, Zhang C, Xiang L (2019) Comparison of efficacy and safety profile for home NB-UVB vs. outpatient NB-UVB in the treatment of non-segmental vitiligo: a prospective cohort study. Photodermatol Photoimmunol Photomed 35(4):261–267. https://doi.org/10.1111/phpp.12462

    Article  CAS  PubMed  Google Scholar 

  24. Totonchy MB, Chiu MW (2014) UV-based therapy. Dermatol Clin 32(3):399-413 ix-x. https://doi.org/10.1016/j.det.2014.03.003

    Article  CAS  PubMed  Google Scholar 

  25. Luo S, Peng Z, Zheng Y, Zhang L, Feng Y, Wang G (2007) Synergistic effects of acitretin and narrow-band UVB on inducing the expression of heparin-binding epidermal-growth-factor-like growth factor in normal human keratinocytes. Arch Dermatol Res 299:409–413. https://doi.org/10.1007/s00403-007-0768-3

    Article  CAS  PubMed  Google Scholar 

  26. Reich A, Mędrek K (2013) Effects of narrow band UVB (311 nm) irradiation on epidermal cells. Int J Mol Sci 14(4):8456–8466. https://doi.org/10.3390/ijms14048456

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Weatherhead SC, Farr PM, Jamieson D, Hallinan JS, Lloyd JJ, Wipat A, Reynolds NJ (2011) Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation. J Invest Dermatol 131(9):1916–1926. https://doi.org/10.1038/jid.2011.134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wu CS, Yu CL, Wu CS, Lan CC, Yu HS (2004) Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 13(12):755–763. https://doi.org/10.1111/j.0906-6705.2004.00221.x

    Article  CAS  PubMed  Google Scholar 

  29. Wu CS, Lan CC, Yu HS (2012) Narrow-band UVB irradiation stimulates the migration and functional development of vitiligo-IgG antibodies-treated pigment cells. J Eur Acad Dermatol Venereol 26(4):456–464. https://doi.org/10.1111/j.1468-3083.2011.04094.x

    Article  CAS  PubMed  Google Scholar 

  30. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77(1):1–13. https://doi.org/10.1016/j.jaad.2016.10.048

    Article  CAS  PubMed  Google Scholar 

  31. Stotts MJ, Adjapong O, Kaplan DE (2019) A psoriasiform drug eruption secondary to nivolumab for hepatocellular carcinoma: a case report. Hepatology 70(4):1477–1479. https://doi.org/10.1002/hep.30659

    Article  PubMed  Google Scholar 

  32. Politi A, Angelos D, Mauri D, Zarkavelis G, Pentheroudakis G (2020) A case report of psoriasis flare following immunotherapy: report of an important entity and literature review. SAGE Open Med Case Rep 13(8):2050313X19897707. https://doi.org/10.1177/2050313X19897707

    Article  Google Scholar 

  33. Koek MB, Buskens E, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Sigurdsson V (2009) Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). BMJ 7(338):b1542. https://doi.org/10.1136/bmj.b1542

    Article  Google Scholar 

  34. Yanovsky RL, Huang KP, Buzney EA (2020) Optimizing narrowband UVB phototherapy regimens for psoriasis. Dermatol Clin 38(1):1–10. https://doi.org/10.1016/j.det.2019.08.001

    Article  CAS  PubMed  Google Scholar 

  35. Dothard EH, Sandoval LF, Yentzer BA, Feldman SR (2015) Home ultraviolet light therapy for psoriasis: why patients choose other options. Dermatol Online J 21(2):11. https://doi.org/10.5070/D3212024299

    Article  Google Scholar 

  36. Torres AE, Lyons AB, Hamzavi IH, Lim HW (2021) Role of phototherapy in the era of biologics. J Am Acad Dermatol 84(2):479–485. https://doi.org/10.1016/j.jaad.2020.04.095

    Article  CAS  PubMed  Google Scholar 

  37. Karaosmanoglu N, Cetinkaya PO, Kutlu O, Karaaslan E, Imren IG, Nalbant EK, Eksioglu M (2020) A cross-sectional analysis of skin cancer risk in patients receiving narrow-band ultraviolet B phototherapy: an evaluation of 100 patients. Arch Dermatol Res 312:249–253. https://doi.org/10.1007/s00403-019-02007-7

    Article  CAS  PubMed  Google Scholar 

  38. Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C, Legoupil D, Pham-Ledard A, Charles J, Pérol M, Gérard E, Combemale P, Bonnet D, Sigal ML, Mahé E; Groupe de Recherche sur le Psoriasis and the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Resopso, Apsoderm and the Groupe Français de Pneumo-Cancérologie (2017) Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 31(5):e254–e257. https://doi.org/10.1111/jdv.14011

    Article  CAS  Google Scholar 

  39. Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152(10):1128–1136. https://doi.org/10.1001/jamadermatol.2016.2226

    Article  PubMed  PubMed Central  Google Scholar 

  40. Jang MS, Park JB, Kim JH, Yang MH, Lee KH, Han SH, Suh KS (2017) Granulocyte colony-stimulating factor-induced psoriasiform dermatitis improved by narrowband ultraviolet B. Ann Dermatol 29(2):232–233. https://doi.org/10.5021/ad.2017.29.2.232

    Article  PubMed  PubMed Central  Google Scholar 

  41. Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I, Aravantinos G, Syrigos K, Stratigos A (2017) Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer 41(6):407–412. https://doi.org/10.1016/j.currproblcancer.2017.10.003

    Article  PubMed  Google Scholar 

  42. Bos WE, Nijsten TE, de Jonge MJ, Hamberg AP (2012) Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome. Arch Dermatol 148(4):546–547. https://doi.org/10.1001/archdermatol.2011.3482

    Article  CAS  PubMed  Google Scholar 

  43. Miyagawa T, Kadono T, Masui Y, Yamada D, Saigusa R, Numajiri H, Omatsu J, Asano Y, Sato S (2017) Nivolumab-induced vitiligo successfully treated with narrowband UVB phototherapy. Eur J Dermatol 27(6):656–658. https://doi.org/10.1684/ejd.2017.3096

    Article  PubMed  Google Scholar 

  44. Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y (2016) Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep 4(4):2324709616674316. https://doi.org/10.1177/2324709616674316

    Article  PubMed  PubMed Central  Google Scholar 

  45. Chia PL, John T (2016) Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC). J Immunother 39(5):202–204. https://doi.org/10.1097/CJI.0000000000000121

    Article  CAS  PubMed  Google Scholar 

  46. İlknur T, Akarsu S, Çarsanbali S, Lebe B, Fetil E (2014) Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma. J Drugs Dermatol 13(8):899–900

    PubMed  Google Scholar 

  47. Borgia F, Saitta C, Vaccaro M, Franzè MS, Lentini M, Cannavò SP (2017) Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: an unconventional skin reaction requiring unconventional treatment. Int J Immunopathol Pharmacol 30(3):327–331. https://doi.org/10.1177/0394632017727618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ohio State University College of Medicine, Columbus, OH, USA

    Candice Park

  2. The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Abraham M. Korman & Brittany L. Dulmage

Authors
  1. Candice Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abraham M. Korman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brittany L. Dulmage
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The initial draft of the manuscript was written by Candice Park, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Brittany L. Dulmage.

Ethics declarations

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, C., Korman, A.M. & Dulmage, B.L. An overview of the efficacy of phototherapy in oncodermatology. Support Care Cancer 30, 5591–5600 (2022). https://doi.org/10.1007/s00520-022-06841-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-022-06841-w

Keywords

Search

Navigation